Orexo´s digital therapies deliver therapeutic interventions to patients to prevent, manage, or treat a medical disorder or disease. The therapies are available for patients in their own privacy 24/7 and can be used as a standalone treatment or together with traditional drugs. Its efficacy has been demonstrated in numerous published clinical trials including thousands of patients.
The therapies are developed based on established cognitive-behavioral therapy technique which is a goal-oriented psychotherapy treatment that takes a hands-on, practical approach to problem-solving. The aim is to provide support and change patterns of thinking or behavior that are behind patients difficulties.
Partnership with Sober Grid
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies VORVIDA® and DEPREXIS®
Pipeline of Digital Therapies
Digital Therapies
Technical development
Registration
Approved and/or Launched
US
EU
RoW
DEPREXIS® Depression
Partner: GAIA AG
Partner: GAIA AG
VORVIDA® Alcohol misuse, incl. alcohol use disorder
Partner: GAIA AG
Partner: GAIA AG
MODIA™ Opioid addiction
Partner: GAIA AG
Partner: GAIA AG
MODIA™ is being tested in a pivotal study
Large pivotal study initiated in June 2021, where the efficacy of MODIA™ is evaluated along with bup/nal pharma treatment.
World-leading technology
Our digital therapies are fully automated developed by GAIA and based on its proprietary artificial intelligence (AI)-expert system, broca®.
DEPREXIS® - one of the most clinically tested digital therapies
DEPREXIS® effectiveness in managing the symptoms of depression has been evaluated and published in 11 randomized clinical trials (RCTs) including more than 2,800 patients.